华润江中更名并发布2025年业绩快报，净利润增长近15%

Core Viewpoint - The company, formerly known as Jiangzhong Pharmaceutical, is rebranding to "China Resources Jiangzhong Pharmaceutical" to enhance synergy with the China Resources brand, marking its full integration into the China Resources system [1] Financial Performance - In the 2025 performance report, the company achieved total revenue of 4.22 billion, a decrease of 4.87% year-on-year; however, net profit attributable to shareholders increased by 14.96% to 906 million, driven by cost control, lean manufacturing, and merger integration [2] Business Development - Since 2025, the company has expanded its product line through acquisitions, such as the purchase of Jingcheng Huyao, while divesting non-core assets like Sanghai Pharmaceutical to focus on high-value businesses. The health sector has shown significant growth, with a 35% year-on-year increase in revenue for the first three quarters of 2025, indicating potential for further development in OTC and health consumer products [3] Strategic Initiatives - In January 2026, the company signed a strategic cooperation agreement with universities to promote collaboration in health services. Additionally, in December 2025, it received dual certification for compliance and anti-bribery management systems, enhancing its governance capabilities, which may positively impact long-term development [4]